Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Ten years after ruxolitinib approval for myelofibrosis: a review of clinical efficacy
Naveen Pemmaraju, Prithviraj Bose, Raajit K. Rampal, et al.
Leukemia & lymphoma/Leukemia and lymphoma (2023) Vol. 64, Iss. 6, pp. 1063-1081
Open Access | Times Cited: 27

Showing 1-25 of 27 citing articles:

The JAK-STAT pathway: from structural biology to cytokine engineering
You Lv, Jianxun Qi, Jeffrey J. Babon, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 15
Small molecule drug discovery targeting the JAK-STAT pathway
You Lv, Pengbing Mi, Jeffrey J. Babon, et al.
Pharmacological Research (2024) Vol. 204, pp. 107217-107217
Open Access | Times Cited: 12
Molecular Genetic Profile of Myelofibrosis: Implications in the Diagnosis, Prognosis, and Treatment Advancements
Tanvi Verma, Nikolaos Papadantonakis, Deniz Peker Barclift, et al.
Cancers (2024) Vol. 16, Iss. 3, pp. 514-514
Open Access | Times Cited: 6
Methodological challenges in the development of endpoints for myelofibrosis clinical trials
Giovanni Barosi, Ayalew Tefferi, Naseema Gangat, et al.
The Lancet Haematology (2024) Vol. 11, Iss. 5, pp. e383-e389
Closed Access | Times Cited: 6
ACVR1: A Novel Therapeutic Target to Treat Anemia in Myelofibrosis
Andrea Duminuco, Helen T. Chifotides, Sebastiano Giallongo, et al.
Cancers (2023) Vol. 16, Iss. 1, pp. 154-154
Open Access | Times Cited: 13
Early intervention with ruxolitinib improves spleen response in patients with myelofibrosis
Pankit Vachhani, Paola Guglielmelli, Janika Repp, et al.
Leukemia & lymphoma/Leukemia and lymphoma (2025), pp. 1-4
Open Access
Treatment patterns and healthcare resource utilization in ruxolitinib-treated patients with myelofibrosis with and without anemia: a real-world analysis
Tom Liu, Mirko Fillbrunn, Shiyuan Zhang, et al.
Annals of Hematology (2025)
Open Access
Therapeutic Inhibition of the JAK-STAT pathway in the treatment of Inflammatory Bowel Disease.
Zihan Chen, Ping Jiang, Dan Su, et al.
Cytokine & Growth Factor Reviews (2024) Vol. 79, pp. 1-15
Closed Access | Times Cited: 4
Red Blood Cell Distribution Width May Predict Drug-Induced Anemia and Prognosis in Patients Affected by Primary/Secondary Myelofibrosis Treated with Ruxolitinib
Alessandro Laganà, Emilia Scalzulli, Ida Carmosino, et al.
Oncology and Therapy (2025)
Open Access
Sometimes Small Is Beautiful: Discovery of the Janus Kinases (JAK) and Signal Transducer and Activator of Transcription (STAT) Pathways and the Initial Development of JAK Inhibitors for IBD Treatment
Jonathan D. Kaunitz
Digestive Diseases and Sciences (2025)
Open Access
Dosing and clinical outcomes of ruxolitinib in patients with myelofibrosis in a real‐world setting: Interim results of the Italian observational study (ROMEI)
Massimo Breccia, Francesca Palandri, Maurizio Martelli, et al.
Cancer (2025) Vol. 131, Iss. 7
Open Access
Primary and secondary myelofibrosis: ophthalmological manifestations at onset and during therapy
Olga Vinogradova, L. B. Egoryan, Д. И. Шихбабаева, et al.
Oncohematology (2025) Vol. 20, Iss. 1, pp. 95-113
Open Access
Managing Myelofibrosis: Matching Advances in Treatments With Clinical Unmet Needs
Chaoyi Wei, Hein Than, Feng‐Ju Huang, et al.
Hematological Oncology (2025) Vol. 43, Iss. S1
Open Access
A Prognostic Model to Predict Ruxolitinib Discontinuation and Death in Patients with Myelofibrosis
Francesca Palandri, Giuseppe A. Palumbo, Massimiliano Bonifacio, et al.
Cancers (2023) Vol. 15, Iss. 20, pp. 5027-5027
Open Access | Times Cited: 7
SHP2 inhibition displays efficacy as a monotherapy and in combination with JAK2 inhibition in preclinical models of myeloproliferative neoplasms
Garima Pandey, Lucia Mazzacurati, Tegan M. Rowsell, et al.
American Journal of Hematology (2024) Vol. 99, Iss. 6, pp. 1040-1055
Open Access | Times Cited: 1
Национальные клинические рекомендации по диагностике и лечению Ph-негативных миелопролиферативных новообразований (истинной полицитемии, эссенциальной тромбоцитемии, первичного миелофиброза) (редакция 2024 г.)
Анаит Левоновна Меликян, Irina N. Subortseva, А. М. Ковригина, et al.
Clinical oncohematology (2024) Vol. 17, Iss. 3, pp. 291-334
Open Access | Times Cited: 1
Clinical and hematological factors predicting the effectiveness of ruxolitinib in primary and secondary myelofibrosis. Results of a prospective single-center study
Olga Vinogradova, M. M. Pankraskina, А. Л. Неверова, et al.
Oncohematology (2024) Vol. 19, Iss. 3, pp. 16-33
Open Access | Times Cited: 1
JAK Inhibitors for Myelofibrosis: Strengths and Limitations
Kyaw Htin Thaw, Claire Harrison, Priya Sriskandarajah
Current Hematologic Malignancy Reports (2024) Vol. 19, Iss. 6, pp. 264-275
Open Access | Times Cited: 1
Treatment Strategies Used in Treating Myelofibrosis: State of the Art
Massimo Martino, Martina Pitea, Annalisa Sgarlata, et al.
Hematology Reports (2024) Vol. 16, Iss. 4, pp. 698-713
Open Access | Times Cited: 1
Cardiovascular Toxicity of Antineoplastic Treatments in Hematological Diseases: Focus on Molecular Mechanisms to Improve Therapeutic Management
Serena Barachini, Gabriele Buda, Iacopo Petrini
Journal of Clinical Medicine (2024) Vol. 13, Iss. 6, pp. 1574-1574
Open Access
The application of JAK inhibitors in the peri-transplantation period of hematopoietic stem cell transplantation for myelofibrosis
Zerong Wang, Xuelian Jin, Jiajia Zeng, et al.
Annals of Hematology (2024) Vol. 103, Iss. 9, pp. 3293-3301
Open Access
Ruxolitinib for myelofibrosis: The earlier, the better?
Prithviraj Bose, Pankit Vachhani
Cancer (2024) Vol. 130, Iss. 24, pp. 4224-4226
Open Access
Spatial-transcriptomic profiling: a new lens for understanding myelofibrosis pathophysiology
Edoardo Peroni, Elisabetta Calistri, Rosario Amato, et al.
Cell Communication and Signaling (2024) Vol. 22, Iss. 1
Open Access
Inhibition of RhoA-mediated secretory autophagy in megakaryocytes mitigates myelofibrosis in mice
Isabelle C. Becker, María N. Barrachina, Joshua Lykins, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
The role of chemokines and interleukins in acute lymphoblastic leukemia: a systematic review
Martin Štajer, Jan M. Horáček, Tomáš Kupsa, et al.
Journal of Applied Biomedicine (2024) Vol. 22, Iss. 4, pp. 165-184
Open Access
Page 1 - Next Page

Scroll to top